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Abstract
While pharmacological and behavioral treatments exist for smoking cessation, there are
currently no best practices for helping adolescents quit smoking. This study aimed to reach consensus
regarding pharmacist recommendations for adolescent smoking cessation. Using a three-round
Delphi technique, pharmacists across the USA with experience working with adolescent substance
use provided quantitative and qualitative feedback on recommendations. Forty pharmacists
completed Round 1, 37 completed Rounds 2 and 3. In Round 1, 36 (90%) responses included the
nicotine patch, gum, or lozenge. Ten recommendations were identified in Round 1: nicotine patch,
nicotine gum, nicotine lozenge, bupropion SR, varenicline, quitline, smoking cessation program,
counseling, behavioral approaches, and cold turkey. In Round 2, pharmacists were most likely
to recommend smoking cessation programs (median=7 of 7, Interquartile range [IQR]=1) and
least likely to recommend varenicline (median=3, IQR=3). In Round 3, consensus to recommend
was reached on smoking cessation program (83.3% likely or very likely to recommend). Despite
initially recommending nicotine replacement therapy in Round 1, by Round 3 most pharmacists
were more likely to recommend behavioral treatments than pharmacological interventions for this
patient population. Such preferences by pharmacists could influence the accessibility of various
treatments to adolescent smokers.

ABBREVIATIONS
NRT: Nicotine Replacement Therapy; IQR: Interquartile
Range

INTRODUCTION

Tobacco use remains the leading preventable cause of disease
and death worldwide [1]. Despite decades of tobacco prevention
initiatives, more than 3,800 teens under 18 try smoking each day
[2]. As their brains are not yet fully developed, adolescents are
more susceptible to the addictive chemicals within combusted
cigarettes, and, therefore, more likely to become addicted despite
sporadic smoking habits [3]. Furthermore, successful quit
attempts among adolescent smokers are rare, perhaps due to
lack of best practice guideline for this population [3].
Behavioral strategies have been used in adolescent smoking
cessation interventions, including cognitive based therapy,
contingency management, and motivational interviewing, in
multiple formats such as telephone-based, internet-based, and
school-based [4]. The most current clinical guideline reported

some evidence for support for counseling (a broad term which
covers multiple behavioral approaches) but stated additional
research is needed in adolescent smoking cessation [3].

Medication options include bupropion slow release (SR)
(i.e. Wellbutrin, Zyban), nicotine gum, nicotine inhaler, nicotine
lozenge, nicotine nasal spray, nicotine patch, and varenicline
pills (i.e. Chantix). Each of these treatment options range in
effectiveness, cost, and insurance coverage and are considered
first-line medications by the tobacco treatment clinical guidelines,
which translates to having an established empirical evidence of
effectiveness [3]. Pharmacological treatments such as the nicotine
patch, nicotine gum, and nicotine lozenge are available overthe-counter within the USA but only to individuals ages 18 and
over. However, such products can be and are obtained by those
under 18, either from friends, family, or doctor prescription [5,6].
Additionally, cessation medications bupropion SR, varenicline,
nicotine nasal spray, and inhaler are available with prescription.
There is mixed evidence among pharmacological
interventions, possibly due to low recruitment and high attrition
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leading to underpowered studies [7]. Some studies show
pharmacological treatments may be helpful for adolescents
looking to quit [8,9], while others report limited success with NRT
[10,11]. Pharmacological treatments for smoking cessation can
improve the odds of successfully quitting by 50-70% [3,12,13].
NRT is widely used and recommended for adult smoking
cessation [3], and is considered the most effective strategy for
quitting when combined with behavioral support [14].
Pharmacists, with training in therapeutics and experience
dispensing medication, offer a unique perspective. While doctors
often prescribe such medications, pharmacists may have greater
observational cessation experience through providing education
alongside medications. Potential for interaction between
pharmacists and adolescent smokers occurs in several settings,
including when youth are obtaining other prescriptions or if youth
are seeking out tobacco or cessation products. Past research with
adolescents and pharmacists in school settings found positive
changes in anti-tobacco knowledge [15]. Additionally, trends
for health education [16-18], vaccinations [19], and smoking
cessation efforts in pharmacies [20], suggest pharmacists may
be an untapped resource for adolescent cessation education.
Furthermore, pharmacist advice or recommendation may play a
role in adolescents using pharmacological treatments for smoking
cessation. Given the potential for pharmacist cessation advice,
this study aimed to address the question: what do pharmacists
recommend for adolescent smoking cessation?

MATERIALS AND METHODS
Delphi overview

A three-round Delphi technique was used to intensively
survey a panel of pharmacists experienced with adolescent
cessation. The technique has been used in medical and health
services research and is suitable for problems when there is
insufficient evidence [21]. Devised in the early 1950s to obtain
feedback from experts, the Delphi technique is a systematic
approach to garner group consensus while minimizing social bias
[22]. Delphi study participants never meet face-to-face which
provides a sense of anonymity and minimizes the influence of
dominant individuals [21].

directors from 47 states and District of Columbia were contacted
via up to two emails over a period of two weeks. Of the 47 directors
contacted, four (Hawaii, Kentucky, Oklahoma, and Wyoming)
responded saying they would share the information, four
(Indiana, Texas, Virginia, and Vermont) provided contact lists for
their members, one (Massachusetts) email link was inactive, 28
did not respond, and 11 responded saying they were not able to
forward the information. Of the 11 state directors who would not
share the information, four (Louisiana, Nebraska, Pennsylvania,
and South Carolina) offered a contact list for purchase, and four
(West Virginia, Missouri, New York, and Kansas) said there was
no list available.

To increase the likelihood of quality responses and ensure
a diverse expert panel, a brief screening tool requesting
information on pharmaceutical background and experience
treating adolescent smokers was administered to all interested
pharmacists. The screener asked potential panel members about
their work setting (e.g. retail, hospital, or research), number of
years practicing, and experience with adolescent smokers.

The literature varies regarding ideal sample size for a
Delphi study, with recommendations for between 20 and 100
participants. Larger samples increase validity, but too large of a
sample can be time intensive, thus delaying the ability to develop
and distribute the second and third rounds of the study [22].
Based on literature recommendations and feasibility, the goal for
the current study was to have 30 pharmacists complete Round
3. Within one week of recruitment, 312 pharmacists completed
the screening survey. All responses to the screening survey
were first reviewed for whether pharmacists had previous
experience working with adolescent smoking cessation. Sixtyseven (21.5%) pharmacists reported minimal or no experience
with adolescent cessation, while an additional 8 (2.6%) provided
unclear responses. From the remaining 237 pharmacists, 50
pharmacists were invited to participate, selected using stratified
random sampling based on years of pharmaceutical experience
and employment sector. Because only those who completed the
previous round were invited to participate in subsequent rounds,
50 participants were invited in order to obtain a final sample of
30 pharmacists.

Procedure

The Delphi technique combines qualitative and quantitative
methodologies, beginning with open-ended items within the first
round and closed-ended survey items within subsequent rounds.
Successive questionnaires give participants feedback on the
collective responses of the group and allow subjects to modify
responses. Throughout, the process builds on the qualitative
responses of the experts and measures the collective response
quantitatively [21]. As such, data collected provide a wealth of
information.

All surveys were conducted via Qualtrics© online software.
Participants were provided the following phrase at the start of
each survey to clarify the target population of adolescents: “The
following items pertain to teen or adolescent smoking. In this
context, teen/adolescent refers specifically to an individual under
the age of 18.” Participants were given two weeks to complete
each survey, with two weeks between each survey for analyses
and received a $50 gift card after completing the final round.

USA State Board of Pharmacy directors were contacted
between May 18 and June 1, 2015, by email, and asked to
share with their members a brief overview of the study and the
screening survey link. Director emails were obtained from the
National Association Boards of Pharmacy website [23]. Of the 50
USA states and District of Columbia listed, all but three (Alabama,
Connecticut, and Tennessee) had email contacts; therefore, the

Round 2: In Round 2, participants who completed Round 1
were asked how likely they were to recommend each treatment

Recruitment

J Pharmacol Clin Toxicol 5(4): 1080 (2017)

Round 1: In Round 1, participants responded to an openended item on recommendations for adolescent smoking
cessation: “What would you recommend for a teen looking to quit
smoking?”. All responses were compiled and categorized by two
independent researchers. Any discrepancies were resolved by a
third researcher.
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identified in Round 1 using a 7-point Likert scale (1 = Very
Unlikely to 7 = Very Likely). Pharmacists were also asked two
items pertaining to tailoring their recommendations, specifically,
whether they were likely to recommend based on adolescent age
and adolescent smoking history.
Round 3: In Round 3, each participant who completed Round
2 was provided a personalized survey link which contained his/
her response alongside the group median and mode from the
previous round for each recommendation. Because the objective
was to determine group consensus, participants were asked to
retain or alter their recommendations and encouraged to provide
commentary as warranted.
Medians and interquartile ranges (IQR) were calculated to
determine consensus. Consensus to recommend was established
for recommendations which received an IQR of 1 and median
rating of at least 6 (Likely to recommend). Qualitative responses
were coded independently by two authors. Any discrepancies
were discussed, with all final codes agreed upon by both coders.
A final question was added to Round 3 based on Round 2
responses. All pharmacists were asked “Is there a particular
Smoking Cessation Program you would recommend?” in order to
identify pharmacist awareness of available programs.

RESULTS AND DISCUSSION
Sample characteristics

Of the 50 pharmacists invited to participate, 40 (80% of
invited) completed Round 1, 37 (92.5% of invited) completed
Rounds 2, and 37 (100% of invited) completed Round 3. The
majority of participants were male (n=23, 62.2%) and White
(n=31, 83.8%), while some identified as African American (n=4,
10.8%), American Indian (n=1, 2.7%), or Asian (n=1, 2.7%).
Participants resided in 14 states: Alabama (n=2), Arizona (n=18),
Florida (n=2), Idaho (n=1), Illinois (n=1), Iowa (n=1), Kentucky
(n=3), Kansas (n=1), Michigan (n=1), Ohio (n=1), Pennsylvania
(n=2), Tennessee (n=1), Texas (n=1), Utah (n=1), and Washington
(n=1). Pharmaceutical experience ranged from three to 48 years,
with on average 19.75 years. Participants worked in both retail
(56.7%) and hospital (43.2%) pharmacies. Participants were
asked whether they had been approached by adolescents seeking
NRT and which products adolescents had requested (if any). Of
the 37 respondents to complete all three rounds of the study,
17 (45.9%) responded they had been approached directly by
an adolescent. Of those, 15 (88.2%) said adolescents requested
nicotine patches, 14 (82.4%) said nicotine gum, 3 (17.6%) said
nicotine lozenges, 2 (11.8%) said nicotine inhalers, and 1 (5.9%)
said e-cigarettes.
Round 1: Forty respondents provided 10 different responses
for the item “What would you recommend for a teen looking to
quit smoking?” Thirty-six (90%) of those responses included an
over-the-counter NRT product (patch, gum, or lozenge). Nicotine
patch and gum were each listed by 23 (57.5%) pharmacists.
Nicotine lozenges, counseling, behavioral approaches (e.g.
identifying triggers and counting strategies), and smoking
cessation programs were each listed by 3 (7.5%) pharmacists.
Varenicline, bupropion SR, quitline, and cold turkey were each
mentioned by 1 (2.5%) pharmacist. Additionally, 5 (12.5%)
J Pharmacol Clin Toxicol 5(4): 1080 (2017)

pharmacists stated their recommendation would be tailored for
age or smoking history.

Thus, 10 recommendations were identified through Round
1: nicotine patch, nicotine gum, nicotine lozenge, bupropion SR,
varenicline, quitline, smoking cessation program, counseling,
behavioral approaches, and cold turkey. Smoking cessation
program refers to a structured quitting program, typically in a
group setting, while counseling refers to individualized guidance,
either formal or not. Behavioral approaches refer to strategies
such as chewing on a peppermint stick or counting to ten.
Round 2: Thirty-seven pharmacists completed Round 2.
Pharmacists were very likely to recommend smoking cessation
programs (median=7 of 7, IQR=1), likely to recommend behavioral
approaches (median=6, IQR=2), counseling (median=6, IQR=2),
quitline (median=6, IQR=3), and nicotine patch (median=6,
IQR=3); somewhat likely to recommend nicotine gum (median=5,
IQR=2) and nicotine lozenge (median=5, IQR=3), and somewhat
unlikely to recommend varenicline (median=3, IQR=3),
bupropion SR (median=3, IQR=3), and cold turkey (median=3,
IQR=4). Pharmacists were likely to base recommendations on
age (median=6, IQR=1) and smoking level (median=6, IQR=1) of
adolescent.

Round 3: Of the 10 recommendations identified in Round 1,
only smoking cessation program met the predetermined criteria
for consensus to recommend, with an IQR of 1, and median score
greater than 5. Of 37 respondents, 30 (81.1%) were likely or very
likely to recommend a smoking cessation program. Remaining
recommendations are in Table 1. The only other item which
reached consensus was nicotine gum (median=5, IQR=1), which
pharmacists were somewhat likely to recommend. Pharmacists
were likely to recommend behavioral approaches (median=6,
IQR=2), counseling (median=6, IQR=2), quitline (median=6,
IQR=3), and nicotine patch (median=6, IQR=3); somewhat
likely to recommend nicotine lozenge (median=5, IQR=2), and
somewhat unlikely to recommend varenicline (median=3,
IQR=2), bupropion SR (median=3, IQR=3), and cold turkey
(median=3, IQR=4). There were 26 (7.0%) response changes
between rounds 2 and 3; however, median response scores did
not change between rounds.
Based on the increased preference in Round 2 for
recommending smoking cessation programs, pharmacists in
Round 3 were asked to list a smoking cessation program they
would recommend. Of the 37 respondents, nine responded, and
only one listed a smoking cessation program. Other pharmacists
responded with cold turkey or quitline which were both other
recommendations and not smoking cessation programs.

Qualitative responses

Participants were given space to provide justifications for
their responses in each round. Participants were not required
to provide comments, but 40% of pharmacists provided a
comment on at least one recommendation (Table 2). Pharmacists
provided several common reasons for their recommendations
including product effectiveness (n=13), cost (n=7), relevance for
adolescents (n=7), accessibility (n=6), and concerns about side
effects (n=15). The qualitative responses provided insight into
some participants’ recommendations. For example, varenicline
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Table 1: Round 2 and Round 3 likelihood counts by recommendation.
R2

Nicotine Patch

R3

R2

Nicotine Gum

R3

R2

Nicotine Lozenge

R3

R2

Bupropion SR

R3

R2

Varenicline

R3

R2

Cold Turkey

R3

R2

Quitline

Smoking
Cessation
Program

Somewhat
Unlikely (3)

Undecided (4)

Somewhat
Likely (5)

Likely (6)

Very Likely
(7)

2

5

2

2

5

17

4

2

3

2

3

3

4

4

8

4

3

3

4

4

9

8

9

8

10

9

6

9

0

6

2

3

7

3

5

12

8

2

7

3

10

3

1

2

4

8

5

7

6

7

3

10

Bupropion SR

13

Varenicline

13

Quitline

13

Cold Turkey
Counseling

Smoking
Cessation
Program
Behavioral
Approaches

3

4

4

4

4

5

13

11
3

3

6

5

6

12
7

2

5

2

3

3

6

5

1

1

3

3

3

3

15

8

14

R3

1

2

3

0

9

9

13

1

0

0

1

1

Number of Commenters

Nicotine Lozenge

5

13

6

Table 2: Qualitative themes by product.

19

0

4

R2

Nicotine Gum

4

10

3

R3

19

16

11

2

R3

Nicotine Patch

7

1

1

0

0

0

0

4

4

3

2

2

Abbreviations: Bold print indicates change between R2 and R3. R2: Round 2; R3: Round 3
Product

1

2

0

R2

Behavioral
Approach

Unlikely (2)

R3

R2

Counseling

Very Unlikely
(1)

11
10
12
7

J Pharmacol Clin Toxicol 5(4): 1080 (2017)

2

1

1

2

1

6

3

3

5

6

9

7

8

10

10

14

22

22

17

17

Comments per Code
5 said effective, 3 said their responses were similar to group response,
3 based on personal experience, 3 said safe, 3 said not the best option, 2 were positive but
vague, 2 said easy to use, 2 said not relevant for adolescents, 1 was concerned about side effects,
1 said accessible, 1 said inexpensive
3 said not the best option, 3 said their responses were similar to group response, 3 said good for
oral substitution, 3 were positive but vague, 2 based on personal experience, 2 said easy to use,
1 said safe, 1 said effective, 1 said not effective, 1 said relevant for adolescents, 1 said accessible,
1 said abuse potential
2 said not the best option, 2 said good for oral substitution, 1 was positive but vague, 1 said their
response was similar to group response, 1 said not effective, 1 said lack of knowledge, 1 said
stigma, 1 said abuse potential
6 were concerned about side effects, 2 said not the best option, 2 said their responses were
similar to group response, 2 based on personal experience, 1 was positive but vague, 1 was
negative but vague, 1 said expensive, 1 said not accessible
8 were concerned about side effects, 2 said not the best option, 2 said their responses were
similar to group response, 1 based on personal experience, 1 was negative but vague, 1 said
expensive, 1 said not accessible
3 said not effective, 2 were positive but vague, 2 were negative but vague, 1 said not the best
option, 1 said safe, 1 said lack of knowledge, 1 said relevant for adolescents
5 were positive but vague, 3 said not the best option, 2 said inexpensive, 1 said safe, 1 said lack
of knowledge, 1 said accessible, 1 said confidential
4 were positive but vague, 2 said not the best option, 2 based on personal experience, 1 said
safe, 1 said not relevant for adolescents, 1 said expensive, 1 said not accessible
3 were positive but vague, 2 based on personal experience, 1 said their response was similar to
group response, 1 said safe, 1 said effective, 1 said easy to use, 1 said lack of knowledge, 1 said
relevant for adolescents, 1 said stigma
3 were positive but vague, 1 said their response was similar to group response, 1 said safe, 1
said effective, 1 said relevant for adolescents, 1 said inexpensive
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and cold turkey received the greatest number of very unlikely
to recommend scores. The comments for varenicline indicate
pharmacists were concerned about the side effects. However,
reasons for recommending or not recommending cold turkey
were less clear.

CONCLUSION

The purpose of this study was to reach consensus on
recommendations for adolescent smoking cessation among
pharmacists. Through a three-round Delphi study, pharmacists
stated and rated their most likely recommendations for
adolescents looking to quit smoking. In the final round,
only smoking cessation program reached consensus for
recommending.

In Round 1, pharmacists were overwhelmingly in favor of
NRT options, with only 25% mentioning anything behaviorally
related. However, in Round 2 and Round 3, pharmacists
were between somewhat unlikely and somewhat likely to
recommended the over-the-counter NRT options, and most
likely to recommend behavioral options. There are several likely
explanations for this: (1) pharmacists may have felt limited to
answers only about medications; (2) pharmacists may have only
been approached about medication options for cessation and
therefore more likely to recommend, or (3) pharmacists may not
be aware of tobacco cessation resources within their community.
As indicated in the screening survey results, pharmacists were
most likely approached for NRT products, which may have
influenced their recommendations. Additionally, as evidenced
by only one person listing a smoking cessation program, while
the pharmacists responded as likely to recommend the smoking
cessation program, it is possible they are not aware of programs,
which may have influenced their initial response, and also limits
the usability.
In the USA, NRT is currently restricted to use among those
18 years of age or older. As the pharmacists in this study were
directed to respond based on likelihood of recommending
for those under 18, some may have been concerned with the
legality of such recommendations. However, none referenced
legal restrictions as a reason for recommending or not
recommending any treatments. Nevertheless, it is possible
current regulations which require prescription for use under 18
influenced some pharmacists’ recommendations. Additionally,
the recommendations identified by this sample of pharmacists
are consistent with current Clinical Practice Guideline [3], though
none referenced that as a reason for selecting any treatment.

There were notable cessation treatment options that were not
recommended within Round 1, and subsequently not discussed
within this survey, including the nicotine inhaler, nicotine nasal
spray, and e-cigarettes. The nicotine inhaler and e-cigarettes
were items for which adolescents had previously approached the
pharmacists within this sample, however, they were not listed
as recommendations by pharmacists in Round 1, and, therefore,
not included throughout the survey. The nicotine inhaler and
nicotine nasal spray are less prevalent among adults, and,
therefore, may be less familiar to pharmacists. The nicotine nasal
spray was found ineffective among one sample of adolescents
[24], but no studies have looked at use of nicotine inhaler. Despite
J Pharmacol Clin Toxicol 5(4): 1080 (2017)

being the most commonly used tobacco product within the USA
among adolescents, e-cigarettes are not considered a cessation
treatment within the USA [25], which may be why pharmacists
did not recommend it as such. However, there is some evidence
young people may use electronic cigarettes for cessation (26),
and, therefore, this should be considered within future studies.

This study contained a number of strengths, as well as
limitations. There were high response rates between Rounds
1 and 3, with all respondents from Round 2 completing
Round 3. Another strength is the abundance of qualitative
feedback. Nearly half of participants voluntarily submitted
qualitative feedback which provided insight into responses.
The first limitation pertains to generalizability. The number of
pharmacists was necessarily limited, and, as such, the findings
may not be generalizable. Additionally, each of the participants
had experience with adolescent substance use, which may not
represent all pharmacists. Second, we failed to operationalize the
term ‘cold turkey’. Recent literature indicates the use of the term
varies. For example, a 2016 study cites ‘cold turkey’ as the best
approach for smoking cessation [27]. However, this usage of the
term does not refer to completely quitting smoking without any
assistance (as was intended by the authors of the current study).
Instead refers to choosing a quit date and stopping smoking
completely as opposed to tapering down, while using NRT or
behavioral treatment. Therefore, future research should clarify
individual interpretations of ‘cold turkey’.
Despite these limitations, this study identified pharmacist
recommendations for adolescent smoking cessation. Results
indicate pharmacists favored behavioral treatments over
pharmacological interventions in this patient population, which
is in agreement with current clinical practice guideline (3).
However, as indicated in this study, pharmacists may not be
familiar with specific behavioral treatments. Such preferences and
knowledge among pharmacists could influence the accessibility
of treatment to adolescent smokers. Future research should
address the possibility of pharmacy-based services for tobacco
cessation, including continuing education for pharmacists
on adolescent tobacco cessation resources. In studies among
adults, pharmacists [28], and patients [29], reported interest in
pharmacy-based cessation. Additionally, qualitative feedbacks
from pharmacists within this sample indicate an interest in
helping youth quit smoking.
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